Related coverage linked through entity extraction aliases.
Mar 01, 2026
Researchers at Adelaide University found that salcaprozate sodium (SNAC), used in oral semaglutide formulations, was associated with gut bacteria changes, elevated inflammatory markers, and reduced brain-derived protein levels in a 21-day animal study.
Feb 21, 2026
New research reveals semaglutide may directly repair cartilage in osteoarthritis patients, while a separate study raises concerns about SNAC, an ingredient used in oral semaglutide formulations, and its effects on gut health.
Feb 18, 2026
A University of South Australia study finds salcaprozate sodium (SNAC), the compound enabling oral semaglutide tablets to work, may alter gut bacteria and increase inflammatory markers in rats, though human effects remain unclear.
Feb 18, 2026
Dr. Reddy's Laboratories is poised to launch generic oral and injectable semaglutide in India following regulatory approval, targeting a market projected to exceed $1 billion driven by 100 million diabetics.
Feb 17, 2026
Novo Nordisk announced on February 4, 2026, that oral semaglutide previously marketed as Rybelsus will be rebranded as oral Ozempic, with availability expected in Q2 2026. The company also filed a patent infringement lawsuit against Hims & Hers over compounded oral semaglutide products.
Feb 10, 2026
Hims and Hers Health pulled its $49 compounded version of Novo Nordisk's Wegovy weight-loss pill after the FDA referred the company to the Department of Justice for potential legal violations.
